Acadia Pharma (ACAD) Tops Q4 EPS by 5c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.42), $0.05 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $121.01 million versus the consensus estimate of $123.2 million.

“Acadia delivered strong financial results in the fourth quarter and full year 2020, driven by robust sales of NUPLAZID in Parkinson’s disease psychosis. Additionally, we made significant advancements in two Phase 3 programs and further expanded our pipeline in pain and neuropsychiatry through strategic business development,” said Steve Davis, Chief Executive Officer. “In 2021, we are focused on delivering continued growth of NUPLAZID, the upcoming potential approval and launch of pimavanserin for dementia-related psychosis and advancing our business development strategy.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance